[1]EL-SERAG HB, RUDOLPH KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology, 2007, 132 (7) :2557-2576.
|
[2]BOTA S, PISCAGLIA F, MARINELLI S, et al.Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma[J].Liver Cancer, 2012, 1 (3-4) :190-200.
|
[3]European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer.EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J].J Hepatol, 2012, 56 (4) :908-943.
|
[4]LEE JH, LEE JM, KIM SJ, et al.Enhancement patterns of hepatocellular carcinomas on multiphasicmultidetector row CT:comparison with pathological differentiation[J].Br J Radiol, 2012, 85 (1017) :e573-e583.
|
[5]NAKANISHI M, CHUMA M, HIGE S, et al.Relationship between diffusion-weighted magnetic resonance imaging and histological tumor grading of hepatocellular carcinoma[J].Ann Surg Oncol, 2012, 19 (4) :1302-1309.
|
[6]HEO SH, JEONG YY, SHIN SS, et al.Apparent diffusion coefficient value of diffusion-weighted imaging for hepatocellular carcinoma:correlation with the histologic differentiation and the expression of vascular endothelial growth factor[J].Korean J Radiol, 2010, 11 (3) :295-303.
|
[7]NASU K, KUROKI Y, TSUKAMOTO T, et al.Diffusion-weighted imaging of surgically resected hepatocellular carcinoma:imaging characteristics and relationship among signal intensity, apparent diffusion coefficient, and histopathologic grade[J].AJR Am J Roentgenol, 2009, 193 (2) :438-444.
|
[8]XU P, ZENG M, LIU K, et al.Microvascular invasion in small hepatocellular carcinoma:is it predictable with preoperative diffusion-weighted imaging?[J].J Gastroenterol Hepatol, 2014, 29 (2) :330-336.
|
[9]WOO S, LEE JM, YOON JH, et al.Intravoxel incoherent motion diffusion-weighted MR imaging of hepatocellular carcinoma:correlation with enhancement degree and histologic grade[J].Radiology, 2014, 270 (3) :758-767.
|
[10]SCHUHMANN-GIAMPIERI G, SCHMITT-WILLICH H, PRESSWR, et al.Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system[J].Radiology, 1992, 183 (1) :59-64.
|
[11]van MONTFOORT JE, STIEGER B, MEIJER DK, et al.Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide Oatp1[J].J Pharmacol Exp T-her, 1999, 290 (1) :153-157.
|
[12]LEE YJ, LEE JM, LEE JS, et al.Hepatocellular carcinoma:diagnostic performance of multidetector CT and MR imaging-asystematic review and meta-analysis[J].Radiology, 2015, 275 (1) :97-109.
|
[13]KIERANS AS, KANG SK, ROSENKRANTZ AB.The diagnostic performance of dynamic contrast-enhanced MR imaging for detection of small hepatocellular carcinoma measuring up to 2cm:a meta-analysis[J].Radiology, 2016, 278 (1) :82-94.
|
[14]ZENG MS, YE HY, GUO L, et al.Gd-EOB-DTPA-enhanced magnetic resonance imaging for focal liver lesions in Chinese patients:a multicenter, open-label, phase III study[J].Hepatobiliary Pancreat Dis Int, 2013, 12 (6) :607-616.
|
[15]KUDO M, MATSUI O, SAKAMOTO M, et al.Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma:consensus at the Symposium of the 48th Annual Meeting of the Liver Cancer Study Group of Japan[J].Oncology, 2013, 84 (Suppl 1) :21-27.
|
[16]Ministry of Health of the People's Republic of China.Diagnosis, management, and treatment of hepatocellular carcinoma (V2011) [J].J Clin Hepatol, 2011, 27 (11) :1141-1158. (in Chinese) 中华人民共和国卫生部.原发性肝癌诊疗规范 (2011年版) [J].临床肝胆病杂志, 2011, 27 (11) :1141-1158.
|
[17]YOO SH, CHOI JY, JANG JW, et al.Gd-EOB-DTPA-enhanced MRI is better than MDCT in decision making of curative treatment for hepatocellular carcinoma[J].Ann Surg Oncol, 2013, 20 (9) :2893-2900.
|
[18]WANG JH, CHEN TY, OU HY, et al.Clinical impact of gadoxetic acid-enhanced magnetic resonance imaging on hepatoma management:a prospective study[J].Dig Dis Sci, 2016, 61 (4) :1197-1205.
|
[19]LEE DH, LEE JM, BAEK JH, et al.Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines:correlation with histopathologic findings[J].Radiology, 2015, 274 (1) :149-160.
|
[20]XIE S, LIU C, YU Z, et al.One-stop-shop preoperative evaluation for living liver donors with gadoxetic acid disodium-enhanced magnetic resonance imaging:efficiency and additional benefit[J].Clin Transplant, 2015, 29 (12) :1164-1172.
|
[21]AHN SS, KIM MJ, LIM JS, et al.Added value of gadoxetic acidenhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma[J].Radiology, 2010, 255 (2) :459-466.
|
[22]KITAO A, MATSUI O, YONEDA N, et al.The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis:correlation with gadoxetic acid enhanced MR imaging[J].Eur Radiol, 2011, 21 (10) :2056-2066.
|
[23]ARIIZUMI S, KITAGAWA K, KOTERA Y, et al.A non-smooth tumor margin in the hepatobiliary phase of gadoxetic acid disodium (Gd-EOB-DTPA) -enhanced magnetic resonance imaging predicts microscopic portal vein invasion, intrahepatic metastasis, and early recurrence after hepatectomy in patients with hepatocellular carcinoma[J].J Hepatobiliary Pancreat Sci, 2011, 18 (4) :575-585.
|
[24]CHOI JY, LEE JM, SIRLIN C.CT and MR imaging diagnosis and staging of hepatocellular carcinoma:part I.Development, growth, and spread:key pathologic and imaging aspects[J].Radiology, 2014, 272 (3) :635-654.
|
[25]WEST CM, Mc KAY MJ, HLSCHER T, et al.Molecular markers predicting radiotherapy response:report and recommendations from an International Atomic Energy Agency technical meeting[J].Int J Radiat Oncol Biol Phys, 2005, 62 (5) :1264-1273.
|
[26]YAMASHITA T, KITAO A, MATSUI O, et al.Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma[J].Hepatology, 2014, 60 (5) :1674-1685.
|
[1] | Yiping LIU, Xinping LI, Lei CHEN, Jinju XIA, Kairong SONG, Ningyang JIA, Wanmin LIU. Accurate imaging diagnosis and recurrence prediction of hepatocellular carcinoma based on artificial intelligence[J]. Journal of Clinical Hepatology, 2022, 38(3): 521-527. doi: 10.3969/j.issn.1001-5256.2022.03.006 |
[2] | Radiology of Infection Sub-branch, Radiology Branch, Chinese Medical Association, Committee on Radiology of Infection, Radiology Branch, Chinese Medical Doctor Association, Radiology Committee on Infectious and Inflammatory Disease, Chinese Research Hospital Association, Radiology of Infection Branch, Working and Treating Committee of HIV/AIDS and STD Association, Radiology of Infectious Disease Management Sub-branch, Infectious Disease Management Branch, Hospital Management Association in China, Beijing Imaging Diagnosis and Treatment Technology Innovation Alliance. Consensus on imaging techniques and diagnostic criteria for hepatitis B virus related early hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(4): 787-791. doi: 10.3969/j.issn.1001-5256.2021.04.013 |
[3] | YANG Xu, SUN WenBing, GAO Jun. Diagnosis and treatment of hepatic vascular tumors[J]. Journal of Clinical Hepatology, 2020, 36(11): 2569-2573. doi: 10.3969/j.issn.1001-5256.2020.11.039 |
[4] | ZHANG ZhongLin, YUAN YuFeng. Key operating points of laparoscopic hepatectomy for liver tumor in difficult locations[J]. Journal of Clinical Hepatology, 2020, 36(12): 2663-2666. doi: 10.3969/j.issn.1001-5256.2020.12.006 |
[5] | Mao YiShen, Xie ZhiBo, Fu DeLiang. An excerpt of IAP/APA/JPS/EPC guidelines for the diagnostic cross sectional imaging and severity scoring of chronic pancreatitis (2018)[J]. Journal of Clinical Hepatology, 2019, 35(1): 72-76. doi: 10.3969/j.issn.1001-5256.2019.01.013 |
[6] | Chen YongPeng, Liang XieEr. Radiological evaluation of the reversal of liver fibrosis and cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(4): 720-723. doi: 10.3969/j.issn.1001-5256.2019.04.004 |
[7] | Chen ZhiSheng, Tang ChenWei, Tang ChaoHui, Tong HuanJun, Jin ZhiWei. Research advances in the clinical diagnosis of intrahepatic cholangiocarcinoma[J]. Journal of Clinical Hepatology, 2019, 35(12): 2638-2643. doi: 10.3969/j.issn.1001-5256.2019.12.005 |
[8] | Wang ZhiYu, Gu SanWei, Chen XiaoQian, Cai YanJun. Clonorchiasis misdiagnosed as hepatic tumor: a case report[J]. Journal of Clinical Hepatology, 2018, 34(3): 602-603. doi: 10.3969/j.issn.1001-5256.2018.03.033 |
[9] | Zhou XinMiao, Liu ZhangChun, Zhou Wei, Qi XingShun. An excerpt of ACR appropriateness criteria chronic liver disease (2017) [J]. Journal of Clinical Hepatology, 2018, 34(1): 44-45. doi: 10.3969/j.issn.1001-5256.2018.01.009 |
[10] | Liu Zhao, Ma WenTing, Zhang PengFei, Li JinKui, Xiao JianXi, Lei JunQiang. Research advances in molecular imaging of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(4): 872-876. doi: 10.3969/j.issn.1001-5256.2018.04.038 |
[11] | Lu NingNing, Sun Bin, Cui XiongWei, Long Jiang, Gao WenFeng, Zheng JiaSheng. Diagnosis and treatment of subcapsular hemorrhage after liver tumor ablation[J]. Journal of Clinical Hepatology, 2017, 33(12): 2326-2330. doi: 10.3969/j.issn.1001-5256.2017.12.014 |
[12] | Wang WenJun, Zhao Yan, Han GuoHong. Radiological evaluation after treatment of hepatocellular carcinoma: criteria and application[J]. Journal of Clinical Hepatology, 2016, 32(1): 62-67. doi: 10.3969/j.issn.1001-5256.2016.01.009 |
[13] | Wang Ran, Qi XingShun, Guo XiaoZhong. LI-RADS Management Working Group consensus on the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(11): 1791-1795. doi: 10.3969/j.issn.1001-5256.2015.11.006 |
[14] | Chen MinHua. Standardization of thermal ablation in treatment of liver tumor[J]. Journal of Clinical Hepatology, 2013, 29(8): 561-563. doi: 10.3969/j.issn.1001-5256.2013.08.001 |
[15] | Yang Shuo, Lu: Dong, Xu YouQing. Research advances in noninvasive diagnosis of nonalcoholic steatohepatitis[J]. Journal of Clinical Hepatology, 2013, 29(12): 901-904. doi: 10.3969/j.issn.1001-5256.2013.12.007 |
[16] | Wang JiPing, Leng JiYan, Cui YaQiong, Zhang Li, Wang Yan. The diagnosis and clinical value of multi-slice spiral CT in children with common liver tumor[J]. Journal of Clinical Hepatology, 2011, 27(7): 718-721. |
[18] | Yang BiWei, Gan YuHong, Ye ShengLong, Zhang BoHeng, Ren ZhengGang, Xia JingLin, Wang YanHong, Ge NingLing, Chen Yi, Li LiXin, Le Fan, Zhang Lan. Necrosis range and safety of radiofrequency combined with systemic chemotherapy and radiofrequency alone.[J]. Journal of Clinical Hepatology, 2004, 20(6): 364-365. |
1. | 张刘璐,吕俊,刘迎春,尧麒,汪静,刘勇. 原发性肝细胞癌不同类型MRI征象分析. 中国CT和MRI杂志. 2023(05): 85-87 . ![]() | |
2. | 游家生,吕秀金,郭伟娟. 动态增强MRI与CT对乙型肝炎肝硬化背景下原发性肝癌的诊断价值. 海南医学. 2022(01): 79-82 . ![]() | |
3. | 郑蕊,李秀芹,代笑梅. 术前彩色多普勒超声血流参数对原发性与转移性肝癌的鉴别诊断价值. 癌症进展. 2022(18): 1926-1929 . ![]() | |
4. | 麦乃全,温惠澄,梁础群. 磁共振弥散加权成像联合动态增强技术对肝内实性结节的诊断价值. 医疗装备. 2021(06): 16-18 . ![]() | |
5. | 贺全富. MSCT灌注成像联合DCE-MRI在肝硬化结节与小肝癌鉴别诊断中的应用. 医药论坛杂志. 2021(06): 126-129 . ![]() | |
6. | 王梅英. 肝细胞性肝癌的超声影像学表现与病理特征. 中国继续医学教育. 2021(15): 124-128 . ![]() | |
7. | 马亦飞. 超声造影联合彩色多普勒超声在鉴别诊断小体积肝脏占位性病变中的价值分析. 现代实用医学. 2021(06): 778-780 . ![]() | |
8. | 李芳,任晓琪. 彩色多普勒超声诊断肝胆管细胞癌和肝细胞肝癌的临床特征. 临床医学研究与实践. 2021(22): 120-121+127 . ![]() | |
9. | 陈孝卫,黄武强,蔡道修. miR-1246和NFIB在肝癌组织中的表达及其与肝癌预后的关系. 东南大学学报(医学版). 2021(06): 772-778 . ![]() | |
10. | 陈家诚,陈小菁,庄春雨,刘富金,罗是是,陈良,武金才,周开伦. 肝内脾异位结节1例报告. 临床肝胆病杂志. 2020(05): 1131-1133 . ![]() | |
11. | 韩利峰,唐秀丽,程秀莲,赵娜. 原发性肝癌血供特点与病理学特性的相关性研究. 中西医结合肝病杂志. 2020(03): 258-260+264 . ![]() | |
12. | 贺莉,乔龙虎,张振奇. 高浓度碘对比剂在肝癌64排螺旋CT动态增强扫描中的效能分析. 中西医结合肝病杂志. 2020(05): 441-443 . ![]() | |
13. | 秦书敏,刘亚良,黄光建,王萌,应可明. 原发性肝细胞癌患者多层螺旋CT及MRI临床诊断价值分析. 中国CT和MRI杂志. 2020(12): 77-79 . ![]() | |
14. | 刘洋,寻航,李修奎,姚鹏飞. 螺旋CT灌注成像与超声超微细血流成像在评估肝癌介入术后活性病灶血供中的应用比较. 中国CT和MRI杂志. 2019(04): 86-88+153 . ![]() | |
15. | 卓涛,陈海燕,陈冬梅,李坚. 超声造影在微小肝细胞肝癌诊断中的应用价值. 临床和实验医学杂志. 2019(07): 766-769 . ![]() | |
16. | 梁伟强,王猛. 术前肝脏储备功能评估的最新研究进展. 新医学. 2019(04): 229-233 . ![]() | |
17. | 祁生平,杨云. MRI和CT影像学检查对肝脏疾病术前诊断及术后恢复的评估. 中国医学装备. 2019(06): 49-52 . ![]() | |
18. | 高德军,韦章诚,陈首名. 1.5T核磁共振动态增强扫描在肝癌分期评估中的临床应用. 实用癌症杂志. 2019(07): 1204-1207 . ![]() | |
19. | 王家友,赵勇,伍小勇. 普美显磁共振对早期肝硬化合并小肝癌的诊断价值. 中国CT和MRI杂志. 2019(08): 92-95 . ![]() | |
20. | 李秀浓,田小银. 全程护患沟通护理在肝癌行肝叶切除术患者中的应用效果研究. 中国现代药物应用. 2019(16): 157-159 . ![]() | |
21. | 陈晓丽,邝菲,李琪红,周冉. 多期增强螺旋CT与超声造影对原发性肝癌的影像学诊断效能对照分析. 中国CT和MRI杂志. 2019(11): 77-80 . ![]() | |
22. | 周婉,金良红. 超声造影及CT定量检测在肝癌介入治疗后疗效评估中的应用. 肝脏. 2019(12): 1422-1425 . ![]() | |
23. | 房海燕,高敏,徐亚运. 经射频消融治疗后复发的微小肝癌患者磁共振图像特点分析. 中国肝脏病杂志(电子版). 2018(01): 50-53 . ![]() | |
24. | 李黎,任思桦,骆成俊,袁涛. 64-MDCT扫描中不同浓度碘对比剂对肝癌不同时相的检出率与增强效果. 局解手术学杂志. 2018(01): 61-64 . ![]() | |
25. | 刘钊,马文婷,张鹏飞,黎金葵,肖建喜,雷军强. 肝细胞癌分子影像诊断进展. 临床肝胆病杂志. 2018(04): 872-876 . ![]() | |
26. | 潘奇,罗春海,马婉玲,曲原飞,王建如,陈琳. 血管内皮生长因子C靶向分子探针在肝细胞癌大鼠模型中的特异性磁共振成像及临床意义. 临床肝胆病杂志. 2018(07): 1492-1496 . ![]() | |
27. | 陈琪萍,林苏,史震山,朱月永,李友炳. 钆塞酸二钠增强磁共振成像与超声在肝细胞癌筛查中的成本效益分析. 临床肝胆病杂志. 2018(09): 1917-1920 . ![]() | |
28. | 罗心晨,周友乾. 从增加高危人群定期筛查依从性谈原发性肝癌早期诊断. 临床肝胆病杂志. 2018(08): 1788-1792 . ![]() | |
29. | 吴杨,施丽丽,房海燕,高敏. 原发性肝癌的CT灌注参数特征及肝脏储备功能评估价值. 中国现代普通外科进展. 2018(04): 309-310 . ![]() | |
30. | 张琳. 多排螺旋CT肝脏多期增强扫描对鉴别肝脏肿瘤的意义探讨. 影像研究与医学应用. 2018(21): 105-106 . ![]() | |
31. | 刘国. 利用超声鉴别诊断肝细胞肝癌、肝胆管细胞癌的临床价值. 影像研究与医学应用. 2018(22): 150-151 . ![]() | |
32. | 张志平,陈飞,戴真煜,姚立正,董从松,刘洋,潘文艳. 肝细胞癌综合治疗后复发的小肝癌患者MRI平扫和动态增强各序列图像表现分析. 医学影像学杂志. 2018(11): 1868-1871 . ![]() | |
33. | 黄超,胡海华,郑银元. 不同影像方法测量原发性肝癌大小的效果比较. 中国现代医生. 2018(28): 125-128 . ![]() |